A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. (Q43040241)
Jump to navigation
Jump to search
scientific article published in April 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels. |
scientific article published in April 2007 |
Statements
A health economic model to assess the cost-effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal alanine aminotransferase levels (English)
Sophie Gerkens
Myriam Nechelput
Lieven Annemans
Bénédict Peraux
Claire Beguin